GNOS Genosis

RNS Number:0247P
Genosis PLC
05 January 2007





For Immediate Release                                             5 JANUARY 2007

                                  GENOSIS PLC

                                 TRADING UPDATE


New Fertell female ovarian reserve test to launch in Boots in February 2007



Genosis plc (RIC: GNOS), ("Genosis" or the "Company"), a UK company focusing on
consumer products for reproductive health, announces a trading update on its
performance as it enters the close period in respect of its preliminary results
for the year ended 31 December 2006.


With effect from January 2006 Genosis signed an exclusive distribution agreement
with The Boots Company plc ("Boots"), the UK's biggest healthcare retailer, to
sell Fertell in its stores. At the time of its interim results, released in
September 2006, Genosis announced that initial sales of Fertell through Boots
were lower than expected; however Boots remains strongly committed to the
distribution of Fertell.


Genosis is therefore pleased to announce today that, in December 2006, it made
further deliveries of the Fertell male and female fertility test to Boots and
that it is broadening the range of the Fertell products sold exclusively through
Boots in the UK. In addition to selling the Fertell male and female fertility
test, Boots will also launch Genosis' Fertell ovarian reserve test in its larger
high street stores and through www.boots.com from February 2007 and has already
placed its initial stocking order of this test.


Genosis has also seen a substantial increase in sales of the couples test via
its own website www.fertell.co.uk., since the redesign of the website in
September 2006. The Fertell ovarian reserve test will also be sold directly by
Genosis through www.fertell.co.uk.


Genosis is in late stage discussions with a select number of major US drug
chains and remains on track to launch Fertell throughout the United States in Q2
of this year.


Genosis' operating results for 2006 are in line with expectations and, as at 31
December 2006, the Company had a net cash position of #2.9 million. The Company
expects to announce its Preliminary results in April 2007.


Paul Bateman, CEO of Genosis said: "The introduction of a further Fertell
product line to be sold in Boots stores will help increase awareness of the
Fertell brand and is a reflection of both the Company's and Boots' belief in the
market opportunity for at-home fertility testing. The launch of Fertell in the
US later this year will be a significant milestone for the Company and we are
encouraged that the product is receiving a positive reception from US
retailers."



For further details, please contact:

Genosis PLC                Paul Bateman, CEO           +44 (0)1483 774 058
                           Jonathan Pockson, CFO
Buchanan Communications    Lisa Baderoon               +44 (0)20 7466 5000                        
Evolution Securities       Tim Worlledge               +44 (0)20 7071 4300
                           Gina Gibson

NOTES TO EDITORS

Genosis is a consumer products company focused on reproductive health. Genosis'
first product Fertell(R), an at-home fertility testing kit for men and women,
went on sale in the UK in January 2006. Fertell(R) was designed and developed by
Genosis and is the first and currently the only OTC product on the high street
that allows couples to accurately test both male and female fertility quickly
and simply in the privacy of their own home. Genosis' product Fertell(R) makes
the breakthrough of taking accepted technology from the laboratory into easy to
use fertility testing devices for testing at home.


Fertell(R) is easy to use. The woman's test is used in a similar way to a
pregnancy test but, unlike any other test that is available for use at home, it
assesses the quality of the egg she releases. For the male test, the man has to
produce a sample, push a button and twist a switch and, in just over an hour,
the test will show him if he has enough motile sperm that can swim to reach an
egg (based on WHO standards). Fertell(R) has been through clinical trials in the
UK and the US and has been shown to be more than 95% accurate when compared with
standard laboratory tests run in fertility clinics. Fertell(R) has been cleared
for sale in the US by the FDA and has received CE marking for sale in Europe.


The Company's first retail distribution agreement is with Boots, the UK's
biggest healthcare retailer with more than 1200 stores nationwide. The Boots
Distribution Agreement is exclusive for the UK until 2008. Boots sells Fertell
through its high street branches in the UK and the Republic of Ireland. The
Fertell kit is also available through www.boots.com and through Genosis' own
website, www.fertell.co.uk.


The potential market for Fertell(R) is estimated to be in excess of US $500
million per annum (Western Europe, North America and Japan). There are in excess
of 500 million couples of reproductive age worldwide, and approximately 1 in 7
or c80 million couples have problems conceiving. There is a significant increase
in the industrialised world in the number of women deferring childbearing until
after 30. This has a marked effect on fertility. Although male factor
infertility is the single most common cause of infertility, the key prognostic
indicator of a couple's fertility is the age of the female partner, with
fertility rates, upon treatments such as IVF, halving between the ages of 30 and
38. In the UK, couples most frequently turn to their medical providers for
assistance, but typically are advised to wait and try to conceive for a further
period of up to 12 months before returning for tests and treatment. The key
benefit of Fertell(R) is that it allows men and women to assess their fertility
status in the privacy of their own home and, the earlier couples can identify
whether a problem exists, the earlier they can seek treatment and the more
likely they are to conceive. The kits are available throughout the UK, through
the internet and will be available in the US in Q2 2007.


www.genosis.com; www.fertell.co.uk


                                  - E N D S -



                      This information is provided by RNS
            The company news service from the London Stock Exchange

END
TSTDZLFBDFBXBBZ

Grafico Azioni Genosis (LSE:GNOS)
Storico
Da Mag 2024 a Giu 2024

Grafico Azioni Genosis (LSE:GNOS)
Storico
Da Giu 2023 a Giu 2024